Does Aetna Cover Farxiga? Coverage Rules, Prior Auth, and Cost-Saving Options Explained

What Is Farxiga and Why Does Coverage Get Complicated?

Farxiga is the brand name for dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by AstraZeneca. The FDA has approved it for three separate indications: glycemic control in type 2 diabetes, reducing hospitalizations in heart failure with reduced ejection fraction, and slowing the progression of chronic kidney disease in adults at risk of progression. [1]

That multi-indication profile is one reason coverage decisions are more complex than for a single-use drug. Aetna may apply different prior-authorization criteria depending on whether the prescription is written for diabetes, heart failure, or CKD. A prior-auth approved for the diabetes indication does not automatically extend to the CKD indication, and vice versa.

Why SGLT2 Inhibitors Sit on Higher Formulary Tiers

SGLT2 inhibitors as a class, including dapagliflozin, empagliflozin (Jardiance), and canagliflozin (Invokana), are brand-name drugs with no generic available in the United States as of early 2025. Because no generic exists, insurers place them on Tier 3 or Tier 4, where cost-sharing is higher. Aetna's standard commercial formulary lists Farxiga on Tier 3 (preferred brand) in many plan designs, but self-insured employer plans that adopt a custom formulary may move it to Tier 4 or exclude it entirely.

How Aetna's Multiple Plan Types Affect Coverage

Aetna operates several distinct plan architectures:

• Commercial fully insured plans (individual and small-group exchange plans, large-group plans): Farxiga is generally covered with prior authorization.
• Self-insured employer plans (ASO arrangements): The employer, not Aetna, sets the drug list. Farxiga could be covered, excluded, or subject to mandatory step therapy.
• Aetna Medicare Advantage: Farxiga coverage depends on the specific Part D benefit attached to the plan. CMS requires Medicare Part D formularies to include at least two drugs per SGLT2 inhibitor class category, so some Medicare Advantage plans do include Farxiga.
• Aetna Medicaid managed care: Coverage depends on the state Medicaid agency's preferred drug list (PDL). Several state PDLs have added dapagliflozin based on cardiovascular and renal outcome data.

The safest approach is to call the member services number on the back of your Aetna ID card or log into your Aetna member portal and search the drug by name before filling a new prescription.

Does Aetna Require Prior Authorization for Farxiga?

Yes. Prior authorization (PA) is required on the majority of Aetna plans that do cover Farxiga. The prior-authorization criteria Aetna typically applies for the type 2 diabetes indication require documentation of an HbA1c above a defined threshold (commonly 7.5% or higher) and evidence that metformin was tried at an adequate dose, unless metformin is contraindicated or not tolerated. [2]

Standard Prior-Authorization Criteria for the Diabetes Indication

Aetna's clinical policy bulletins, which are publicly available on aetna.com, outline what the prescriber must submit. Common documentation requirements include:

1. A confirmed diagnosis of type 2 diabetes with a recent HbA1c result.
2. Documentation that the patient has tried at least one first-line agent (metformin 1,000 mg twice daily for at least 8-12 weeks) unless contraindicated.
3. Documentation that the SGLT2 inhibitor is being prescribed for cardiovascular risk reduction, glycemic control, or both (the specific clinical rationale matters for approval).
4. EGFR result, because dapagliflozin is not recommended when eGFR falls below 25 mL/min/1.73 m² for the diabetes indication. [1]

The American Diabetes Association's 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor with demonstrated benefit is recommended as part of the glucose-lowering regimen." [3] Quoting or attaching this guideline language in the PA submission can strengthen the clinical justification.

Prior Authorization for Heart Failure and CKD Indications

For the HFrEF indication, Aetna typically requires:

• A confirmed diagnosis of heart failure with reduced ejection fraction (LVEF generally 40% or below).
• Documentation of GDMT (guideline-directed medical therapy) including a beta-blocker, ACE inhibitor/ARB/ARNI, and mineralocorticoid receptor antagonist if tolerated.

The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg daily reduced the composite of worsening heart failure or cardiovascular death by 26% (HR 0.74, 95% CI 0.65-0.85, P<0.001) compared with placebo, regardless of whether patients had diabetes. [4] Citing this trial directly in the PA letter provides a strong evidence basis.

For the CKD indication, clinical policy typically requires:

• eGFR between 25 and 75 mL/min/1.73 m² (the range studied in the DAPA-CKD trial).
• A urine albumin-to-creatinine ratio (UACR) of 200 mg/g or higher.
• Stable dose of an ACE inhibitor or ARB unless contraindicated.

The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the primary composite of sustained 50% decline in eGFR, end-stage kidney disease, or death from renal or cardiovascular causes by 39% (HR 0.61, 95% CI 0.51-0.72, P<0.001). [5] The trial was stopped early because the benefit was so clear.

What Is Step Therapy and Does It Apply to Farxiga?

Step therapy means Aetna requires a patient to try and fail (or have a documented contraindication to) one or more lower-tier drugs before approving Farxiga. For the type 2 diabetes indication, step therapy commonly requires:

• Step 1: Metformin (generic, very low cost).
• Step 2: A sulfonylurea or DPP-4 inhibitor (sometimes required on more aggressive formularies).

If your prescriber writes the Farxiga prescription without documenting prior therapy, the PA will almost certainly be denied on step-therapy grounds. Step therapy requirements for the heart failure and CKD indications are less common but not unheard of on certain employer plans.

How Step Therapy Can Be Waived

Most states now have "step therapy override" laws that require insurers to grant an exception if the required first-step drug is contraindicated, caused adverse effects, or was previously tried without adequate benefit. As of 2024, more than 30 states have enacted such protections. [6] If your prescriber can document that metformin is contraindicated (e.g., because of advanced CKD with eGFR <30, or intolerance) or was previously tried without adequate glycemic control, Aetna must review that exception request.

How to Appeal a Farxiga Coverage Denial

Aetna denials are not final. The standard appeal pathway has three stages.

Stage 1: Internal Appeal

File within the timeframe stated on your denial letter (typically 180 days for a standard appeal). Your prescriber's office should submit:

• A letter of medical necessity referencing specific trial data (DAPA-HF, DAPA-CKD, or DECLARE-TIMI 58 as appropriate).
• The relevant ADA, ACC/AHA, or KDIGO guideline recommendation.
• All lab results (HbA1c, eGFR, UACR, echocardiogram if applicable).
• Documentation of prior therapies tried.

The DECLARE-TIMI 58 trial (N=17,160) showed that dapagliflozin significantly reduced the rate of hospitalization for heart failure (HR 0.83, 95% CI 0.73-0.95, P=0.005) in a broad type 2 diabetes population, including patients without established cardiovascular disease. [7] This data is relevant when arguing that the drug is appropriate even for patients who have not yet had a cardiovascular event.

Stage 2: External Independent Review

If Aetna upholds the denial internally, you are entitled to an external review by an independent organization (required under ACA rules for most plans). External reviewers overturn internal denials at a meaningful rate, particularly when the prescription aligns with major guideline recommendations.

Stage 3: State Insurance Commissioner Complaint

If external review is also denied, filing a complaint with your state's insurance department is a legal option. State regulators have authority to require insurers to comply with their own clinical policy documents and state formulary laws.

How Much Does Farxiga Cost Through Aetna?

Out-of-pocket cost depends on your specific plan's cost-sharing design.

Tier 3 Cost-Sharing on Typical Aetna Plans

On a standard commercial plan with a Tier 3 benefit, a 30-day supply of Farxiga 10 mg costs roughly $50-$100 after deductible, once you have met your deductible. Before meeting the deductible on a high-deductible health plan (HDHP), you may pay the full negotiated rate, which typically sits between $400 and $520 per month after Aetna's contracted discount.

Medicare Advantage Part D Cost-Sharing

On Aetna Medicare Advantage plans with a Part D drug benefit, dapagliflozin is typically placed in the Tier 4 or Tier 5 (specialty) category during the initial coverage phase. Cost-sharing can range from $47 to over $100 per month depending on the specific plan. After reaching the out-of-pocket maximum (the redesigned $2,000 OOP cap under the Inflation Reduction Act, effective 2025), your cost drops to $0. [8]

Using the AstraZeneca Savings Card

AstraZeneca operates an assistance program called AZ&Me and a commercial savings card program. Commercially insured patients who meet eligibility criteria (not enrolled in a federal program like Medicare or Medicaid) may pay as low as $0 per month. The savings card can be used at most retail pharmacies regardless of whether Farxiga is on the Aetna formulary, because it functions as a secondary payer at the pharmacy counter. Patients on Medicare are not eligible for manufacturer copay cards but may qualify for AZ&Me, a separate income-based patient assistance program that provides Farxiga at no cost.

Farxiga Formulary Alternatives on Aetna Plans

If Farxiga is not covered or is too expensive under your specific Aetna plan, your prescriber may consider therapeutically equivalent or clinically similar options.

Other SGLT2 Inhibitors

• Jardiance (empagliflozin): Also an SGLT2 inhibitor with FDA approval for type 2 diabetes, HFrEF, heart failure with preserved ejection fraction (HFpEF), and CKD. The EMPA-REG OUTCOME trial (N=7,020) showed a 38% reduction in cardiovascular death. [9] Some Aetna plans tier Jardiance more favorably than Farxiga.
• Invokana (canagliflozin): FDA-approved for type 2 diabetes and CKD. The CREDENCE trial (N=4,401) demonstrated a 30% reduction in the primary renal composite. [10] Canagliflozin carries an additional FDA warning for lower-limb amputation risk.

GLP-1 Receptor Agonists as an Alternative Class

If an SGLT2 inhibitor is entirely blocked by formulary restrictions, a GLP-1 receptor agonist (semaglutide, dulaglutide) is a guideline-recommended alternative for cardiovascular risk reduction in type 2 diabetes. Coverage and cost-sharing differ, and your prescriber should check the specific Aetna formulary before switching.

HealthRX Decision Framework: Navigating Aetna Farxiga Coverage in Four Steps

Use this workflow before your next pharmacy visit:

1. Check the formulary first. Log into your Aetna member portal, search "dapagliflozin" or "Farxiga," and note the tier and any PA/step-therapy flags. If the plan excludes it entirely, go directly to Step 3.
2. Request a PA proactively. Ask your prescriber's office to submit a PA with lab documentation (HbA1c, eGFR, UACR) and a letter citing the relevant guideline (ADA 2024 Standards, ACC/AHA heart failure guidelines, or KDIGO 2022 CKD guideline) before the prescription is sent to the pharmacy. A proactive PA is faster than a reactive denial appeal.
3. Apply the AstraZeneca savings card immediately. If you are commercially insured (not Medicare/Medicaid), activate the card at farxiga.com while the PA processes. This caps cost during any interim fill at a retail pharmacy.
4. Appeal with trial data. If the PA is denied, have your prescriber cite DAPA-HF (N=4,744, 26% reduction in HF events) [4] or DAPA-CKD (N=4,304, 39% reduction in renal composite) [5] in the appeal letter, and attach the ADA or KDIGO guideline statement. External reviews resolve within 72 hours for urgent cases.

Checking Your Specific Aetna Plan: Step-by-Step

Coverage questions are most reliably answered through three official channels:

The Aetna Member Portal

After logging in at aetna.com, select "Pharmacy" and then "Drug Cost and Coverage." Type "dapagliflozin" (generic name) or "Farxiga" (brand name). The tool displays:

• Whether the drug is on your formulary.
• The tier and estimated cost at different pharmacies.
• Any PA, step therapy, or quantity limit requirements.

Calling Member Services

Call the number on the back of your card. Ask specifically: "Is Farxiga (dapagliflozin) covered under my plan? What tier is it on? Is prior authorization required? Is there a step therapy requirement?"

Write down the representative's name, the date, and the reference number for the call. This record is useful if a pharmacy claim is later denied and you need to demonstrate that coverage was confirmed verbally.

Asking Your Prescriber's Office to Run an ePriorAuth

Most electronic health record (EHR) systems now support electronic prior-authorization (ePA) submissions directly to Aetna. A properly submitted ePA typically receives a decision within 1-3 business days for standard requests and within 72 hours for urgent requests. Your prescriber's office can initiate this process before your appointment ends.

Clinical Rationale: Why Prescribers Fight for Farxiga Coverage

The ACC/AHA 2022 Heart Failure Guidelines give a Class I recommendation (Level of Evidence A) to SGLT2 inhibitors for patients with HFrEF to reduce cardiovascular mortality and hospitalizations. [11] The KDIGO 2022 Diabetes Management in CKD guideline recommends dapagliflozin or empagliflozin for patients with type 2 diabetes and CKD who have an eGFR of at least 20 mL/min/1.73 m², regardless of glycemic status. [12]

These are not weak recommendations. A Class I guideline recommendation means the guideline writing committee judged that the benefit substantially outweighs the risk and that the evidence from multiple high-quality randomized controlled trials is consistent. When a prescriber submits an appeal citing a Class I recommendation, the clinical foundation for overturning a denial is strong.

Dr. John McMurray, lead investigator of the DAPA-HF trial, stated: "Dapagliflozin reduced the risk of worsening heart failure or death from cardiovascular causes, regardless of the presence or absence of diabetes, and was well tolerated." [4] This statement, sourced from the published trial, can be quoted directly in an appeal letter.

What Happens If Farxiga Is Not on Your Aetna Formulary at All?

A small number of Aetna employer-sponsored plans exclude SGLT2 inhibitors from the formulary entirely. In that case, your options are:

• Formulary exception request: Ask your prescriber to submit a medical exception request showing that no covered alternative is clinically appropriate for your condition.
• Appeals based on essential health benefit (EHB) rules: ACA marketplace plans are required to cover essential health benefits, and excluding all drugs in a therapeutic category without clinical justification may violate this rule.
• AZ&Me patient assistance program: If your household income qualifies, AstraZeneca provides Farxiga at no cost through the AZ&Me program, independent of insurance coverage.
• Plan change during open enrollment: If your employer offers multiple plan options, compare the drug formularies before selecting your plan for the next year.